Preclinical News and Research

RSS

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Now, new research published in the journal Hippokratia focuses on assisting the ongoing COVID-19 therapeutic research by developing a new method to identify active compounds that have the potential to fight against COVID-19 infection.

15 Jul 2021

A small molecule inhibitor shows promise to reduce the growth of uveal melanoma

Uveal melanoma, or UM, is a rare and deadly cancer of the eye, and the mortality rate has remained unimproved for 40 years. Half of the melanomas spread to other organs of the body, causing death in less than a year, so new treatments to preserve vision and prevent death are an urgent need.

15 Jul 2021

Yale School of Public Health and Tevogen Bio partner to expand school's regulatory sciences program

The Yale School of Public Health is partnering with Tevogen Bio, a clinical stage biotechnology company, on a major expansion of the school's regulatory sciences program.

14 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Curia today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization.

From Curia 13 Jul 2021

Static magnetic field from MRI scanner decreases blood-brain barrier opening volume

MRI-guided focused ultrasound combined with microbubbles can open the blood-brain barrier (BBB) and allow therapeutic drugs to reach the diseased brain location under the guidance of MRI.

13 Jul 2021

New approach that uses machine learning could transform drug development

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.

12 Jul 2021

Study opens up new opportunities for controlling tuberculosis

Boosting the body's own disease-fighting immune pathway could provide answers in the desperate search for new treatments for tuberculosis.

12 Jul 2021

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

The drugmaker Pfizer, one of the companies behind the Pfizer-BioNTech vaccine, or BNT162b2, awaits the green light to develop a COVID-19 booster shot that can protect against emerging variants. Pfizer’s COVID-19 vaccine has been shown to be 95% effective in an ongoing large-scale clinical trial against the original SARS-CoV-2 strain.

11 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Intranasal COVID-19 vaccine protects animals against lethal COVID-19 infection

In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection.

8 Jul 2021

Repurposed drugs for COVID-19 treatment identified through virtual screening and cell-based assays

A joint research group from KAIST and Institut Pasteur Korea has identified repurposed drugs for COVID-19 treatment through virtual screening and cell-based assays.

8 Jul 2021

Genetic map reveals potential new treatment for aggressive childhood brain tumor

A genetic map of an aggressive childhood brain tumor called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease.

7 Jul 2021

Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis

Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

7 Jul 2021

Research team identifies a way to improve immune response during viral infections

Melbourne researchers have identified a way to improve the immune response in the face of severe viral infections.

6 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

A compelling report, recently released on the bioRxiv* preprint server, describes unexpectedly powerful inhibition of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by thiol-based mucolytic compounds P2119 and P2165, by preventing the virus spike from binding to its host cell receptor, the angiotensin-converting enzyme 2 (ACE2).

5 Jul 2021

Loss of PTHrP hormone can prevent metastases, improve survival in mice with pancreatic cancer

Lowering levels of a hormone called PTHrP can prevent metastases and improve survival in mice with pancreatic cancer and could lead to a new way to treat patients, according to a study from cancer researchers at Columbia University Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center and with collaborators at the University of Pennsylvania.

1 Jul 2021

New research receives $2 million grant to determine if meningitis, sepsis increase Alzheimer's risk

The role of peripheral and brain infections in the development of Alzheimer's disease is the focus of new research at The University of Texas Health Science Center at Houston, funded with a $2 million grant from the National Institutes of Health.

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.